NCT07523581Phase 2Recruiting

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Study sponsor: Eloxx Pharmaceuticals, Inc. · ELOX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06-30Estimated
Enrollment · participants24Estimated
Source updated2026-09-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source